Human Anti-HIV-1 gp120 Recombinant Antibody (clone 2.2c) (CAT#: PABL-161)

Recombinant Human Antibody (2.2c) is capable of binding to HIV-1 gp120 A32-like epitope, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp120 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 gp120 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Representative ADCC curves for MAbs N5-i5 and 2.2c.

Figure 1 Representative ADCC curves for MAbs N5-i5 and 2.2c.

ADCC assays were performed using CEM-NKr-CCR5 target cells sensitized with gp120 of the HIV-1BaL isolate.

Acharya, P., Tolbert, W. D., Gohain, N., Wu, X., Yu, L., Liu, T.,... & Luongo, T. S. (2014). Structural definition of an antibody-dependent cellular cytotoxicity (ADCC) response implicated in reduced risk for HIV-1 infection. Journal of virology, JVI-02194.

Figure 2 Exposure of N5-i5 and 2.2c epitopes on a viral trimer.

Figure 2 Exposure of N5-i5 and 2.2c epitopes on a viral trimer.

(A) Colocalization of N5-i5 and 2.2c epitopes within the virion-associated untriggered HIV-1 trimers. The Cα atoms of gp120 residues involved in interaction with N5-i5 (blue balls) and 2.2c (pink balls) are mapped into the trimer structure derived by cryo-electron tomography and are shown as blue and pink balls, respectively. (B) Colocalization of N5-i5 and 2.2c epitopes within HIV-1 trimers triggered with the soluble CD4. N5-i5 and 2.2c epitope footprints were mapped in the structure derived by cryo-electron tomography of the gp120Bal-d1d2CD4 trimer. The mapping of N5-i5 and 2.2c epitope footprints in the tomograms confirms that they stay largely within the interface of d1d2CD4-triggered spike and are not available for antibody recognition, due to steric hindrance. (C) The binding curves of MAb N5-i5 (red line) and 2.2c (green line) to surface-expressed HIV-1BaL trimers in the presence or absence of soluble d1-d4CD4 (sCD4). CD4i antibody 17b (cyan line) was used as a positive control. The enhancement of binding to sCD4-triggered HIV-1BaL trimers was observed only for coreceptor binding site MAb 17b. (D) MAb N5-i5 binding (solid lines) and 2.2c binding (dashed lines) to CEM-Nkr-CCR5+ cells (left) or CEM-Nkr-CCR5− cells (right). The rightmost curves (red) in each histogram overlay represent the binding of N5-i5 or 2.2c to virion-sensitized cells, whereas the leftmost curves (blue) represent the binding of these MAbs on cells not sensitized with virions.

Acharya, P., Tolbert, W. D., Gohain, N., Wu, X., Yu, L., Liu, T.,... & Luongo, T. S. (2014). Structural definition of an antibody-dependent cellular cytotoxicity (ADCC) response implicated in reduced risk for HIV-1 infection. Journal of virology, JVI-02194.

Figure 3 MAb N5-i5 and 2.2c binding to the gp120 antigen.

Figure 3 MAb N5-i5 and 2.2c binding to the gp120 antigen.

(A) Superimposition of N5-i5 Fab-gp12093TH057 coree-d1d2CD4 and 2.2c Fab-gp12089.6P coree-d1d2CD4 complexes. Structures were aligned based on the gp120 molecule; a molecular surface is displayed over N5-i5 Fab, and 2.2c Fab is shown in a ribbon diagram. (B) MAb N5-i5 and 2.2c binding kinetics to gp120-sensitized CEM-Nkr-CCR5+ target cells, as measured with an unlabeled MAb competition protocol. CEM-Nkr-CCR5+ target cells were sensitized with gp120, and a saturation curve was developed as described in Materials and Methods. (C) Scatchard plots of N5-i5 and 2.2c binding to CEM-Nkr-CCR5+ target cells were derived from the binding data using the standard equation by nonlinear curve fitting.

Acharya, P., Tolbert, W. D., Gohain, N., Wu, X., Yu, L., Liu, T.,... & Luongo, T. S. (2014). Structural definition of an antibody-dependent cellular cytotoxicity (ADCC) response implicated in reduced risk for HIV-1 infection. Journal of virology, JVI-02194.

Figure 4 Fv-swapped versions of N5-i5 and 2.2c.

Figure 4 Fv-swapped versions of N5-i5 and 2.2c.

(A) Design of Fv-swapped versions of N5-i5 and 2.2c. Swaps were made by moving the variable heavy (VH) domain onto the constant light (CL) domain and the variable light (VL) domain onto the constant heavy 1 (CH1) domain for each MAb to replicate the Fc domain orientations of counterpart. (B) Half-maximal binding of MAbs N5-i5 and 2.2c and their swapped versions to gp120-sensitized CEM-Nkr-CCR5+ target cells. Each binding experiment was repeated independently four to seven times as described in Materials and Methods, and half-maximal-binding and Bmax values were pooled for statistical analysis. (C) Cytotoxicity mediated by MAbs N5-i5 and 2.2c and their swapped versions on gp120-sensitized CEM-Nkr-CCR5+ target cells.

Acharya, P., Tolbert, W. D., Gohain, N., Wu, X., Yu, L., Liu, T.,... & Luongo, T. S. (2014). Structural definition of an antibody-dependent cellular cytotoxicity (ADCC) response implicated in reduced risk for HIV-1 infection. Journal of virology, JVI-02194.


Specifications

  • Host Species
  • Human
  • Type
  • Human IgG1
  • Species Reactivity
  • HIV-1
  • Clone
  • 2.2c
  • Applications
  • WB, ELISA, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for ADCC. For details, refer to published data.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160; precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 2.2c"

See other products for "HIV-1 gp120"

Chimeric Antibody

CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG

Humanized Antibody

CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment WB, ELISA, FuncS Human scFv

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-161. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare